DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1939)

Obesity/Overweight | Current Treatment | Detailed, Expanded Analysis (US)

Obesity/Overweight | Current Treatment | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Obesity is arguably the most pressing public health issue in the United States. The prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and adverse cardiovascular health. Historically, therapies have struggled to elicit meaningful weight loss without compromising the overall risk-benefit of intervention. Following a long period without any treatment options, the 2012-2017 period saw several new treatment options launch for obesity. In this report, U.S. primary care physicians (PCPs) and endocrinologists reveal their prescribing patterns for antiobesity drugs and describe what factors drive their drug selection.

QUESTIONS ANSWERED

  • Of the patients drug-treated for weight loss, what percentage receive each of the key brands, such as Novo Nordisk’s Saxenda or Vivus’s Qsymia?
  • What percentage of obese patients receive off-label treatment for weight loss with drug classes such as the SGLT-2 inhibitors?
  • How do antiobesity prescribing patterns change between lines of therapy?
  • How frequently are physicians prescribing combinations of antiobesity drugs, and which are their preferred combinations?
  • Which factors drive or constrain physicians’ prescribing practices? How do PCPs and specialists differ in their approach to treatment?

GEOGRAPHIES

United States.

PRIMARY RESEARCH

Survey of 40 U.S. PCPs and 60 U.S. endocrinologists.

KEY DRUGS COVERED

Saxenda, Contrave, Belviq, Qsymia, Xenical, phentermine.

KEY INSIGHTS PROVIDED

Factors influencing disease management and treatment decisions.

Drivers and constraints of treatment selection.

Physician-reported treatment practices and brand-level patient shares.

Rationale for changes in treatment approach.

Physician insightsinto persistency and compliance.

Physician-reported recent/anticipated changes in brand usage or treatment approach.

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights Obesity/Overweight US April 2019

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)
  • Rameshwar Prajapati, (Pharm.), is an Associate Analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on metabolic and renal diseases. In this role, his main function is to perform primary and secondary research across the team’s range of therapeutic indications and provide insights and assessments for related pharmaceutical ; Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, ;

Purchase Report

Recent reports:
You may also be interested in: